643 related articles for article (PubMed ID: 31469249)
1. Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus.
Ramsey-Goldman R; Alexander RV; Massarotti EM; Wallace DJ; Narain S; Arriens C; Collins CE; Saxena A; Putterman C; Kalunian KC; O'Malley T; Dervieux T; Weinstein A
Arthritis Rheumatol; 2020 Jan; 72(1):78-88. PubMed ID: 31469249
[TBL] [Abstract][Full Text] [Related]
2. A Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified Lupus.
Ramsey-Goldman R; Alexander RV; Conklin J; Arriens C; Narain S; Massarotti EM; Wallace DJ; Collins CE; Saxena A; Putterman C; Brady K; Kalunian KC; Weinstein A
ACR Open Rheumatol; 2021 Feb; 3(2):116-123. PubMed ID: 33538130
[TBL] [Abstract][Full Text] [Related]
3. Cell-bound complement activation products associate with lupus severity in SLE.
Arriens C; Alexander RV; Narain S; Saxena A; Collins CE; Wallace DJ; Massarotti E; Conklin J; Kalunian KC; Putterman C; Ramsey-Goldman R; Buyon JP; Askanase A; Furie RA; James JA; Bello GA; Manzi S; Ahearn J; O'Malley T; Weinstein A; Dervieux T
Lupus Sci Med; 2020 Apr; 7(1):. PubMed ID: 32371480
[TBL] [Abstract][Full Text] [Related]
4. Brief Report: How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria.
Mosca M; Costenbader KH; Johnson SR; Lorenzoni V; Sebastiani GD; Hoyer BF; Navarra S; Bonfa E; Ramsey-Goldman R; Medina-Rosas J; Piga M; Tani C; Tedeschi SK; Dörner T; Aringer M; Touma Z
Arthritis Rheumatol; 2019 Jan; 71(1):91-98. PubMed ID: 30035365
[TBL] [Abstract][Full Text] [Related]
5. Using the American College of Rheumatology (ACR) and Systemic Lupus International Collaborating Clinics (SLICC) criteria to determine the diagnosis of systemic lupus erythematosus (SLE) in patients with subacute cutaneous lupus erythematosus (SCLE).
Tiao J; Feng R; Carr K; Okawa J; Werth VP
J Am Acad Dermatol; 2016 May; 74(5):862-9. PubMed ID: 26897388
[TBL] [Abstract][Full Text] [Related]
6. Cell-bound complement activation products (CB-CAPs) have high sensitivity and specificity in pediatric-onset systemic lupus erythematosus and correlate with disease activity.
Hui-Yuen JS; Gartshteyn Y; Ma M; O'Malley T; Conklin J; Eichenfield AH; Imundo LF; Dervieux T; Askanase AD
Lupus; 2018 Dec; 27(14):2262-2268. PubMed ID: 30376789
[TBL] [Abstract][Full Text] [Related]
7. Probable systemic lupus erythematosus with cell-bound complement activation products (CB-CAPS).
Lamichhane D; Weinstein A
Lupus; 2016 Aug; 25(9):1050-3. PubMed ID: 26911153
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Sensitivities of American College of Rheumatology and Systemic Lupus International Collaborating Clinics Classification Criteria in Childhood-onset Systemic Lupus Erythematosus.
Tao JJ; Hiraki LT; Levy DM; Silverman ED
J Rheumatol; 2019 Jul; 46(7):731-738. PubMed ID: 30770510
[TBL] [Abstract][Full Text] [Related]
9. Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity.
Kim AHJ; Strand V; Sen DP; Fu Q; Mathis NL; Schmidt MJ; Bruchas RR; Staten NR; Olson PK; Stiening CM; Atkinson JP
Arthritis Rheumatol; 2019 Mar; 71(3):420-430. PubMed ID: 30294950
[TBL] [Abstract][Full Text] [Related]
10. Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus.
Kalunian KC; Chatham WW; Massarotti EM; Reyes-Thomas J; Harris C; Furie RA; Chitkara P; Putterman C; Gross RL; Somers EC; Kirou KA; Ramsey-Goldman R; Hsieh C; Buyon JP; Dervieux T; Weinstein A
Arthritis Rheum; 2012 Dec; 64(12):4040-7. PubMed ID: 22932861
[TBL] [Abstract][Full Text] [Related]
11. Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus.
Liu CC; Kao AH; Hawkins DM; Manzi S; Sattar A; Wilson N; Ahearn JM
Clin Transl Sci; 2009 Aug; 2(4):300-8. PubMed ID: 20161444
[TBL] [Abstract][Full Text] [Related]
12. Validation of a multi-analyte panel with cell-bound complement activation products for systemic lupus erythematosus.
Dervieux T; Conklin J; Ligayon JA; Wolover L; O'Malley T; Alexander RV; Weinstein A; Ibarra CA
J Immunol Methods; 2017 Jul; 446():54-59. PubMed ID: 28389175
[TBL] [Abstract][Full Text] [Related]
13. Cell-bound complement activation products (CB-CAPs) as a source of lupus biomarkers.
Calano SJ; Shih PA; Liu CC; Kao AH; Navratil JS; Manzi S; Ahearn JM
Adv Exp Med Biol; 2006; 586():381-90. PubMed ID: 16893085
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal anti-nuclear antibody (ANA) seroconversion in systemic lupus erythematosus: a prospective study of Swedish cases with recent-onset disease.
Frodlund M; Wetterö J; Dahle C; Dahlström Ö; Skogh T; Rönnelid J; Sjöwall C
Clin Exp Immunol; 2020 Mar; 199(3):245-254. PubMed ID: 31778219
[TBL] [Abstract][Full Text] [Related]
15. Classification of Systemic Lupus Erythematosus: Systemic Lupus International Collaborating Clinics Versus American College of Rheumatology Criteria. A Comparative Study of 2,055 Patients From a Real-Life, International Systemic Lupus Erythematosus Cohort.
Inês L; Silva C; Galindo M; López-Longo FJ; Terroso G; Romão VC; Rúa-Figueroa I; Santos MJ; Pego-Reigosa JM; Nero P; Cerqueira M; Duarte C; Miranda LC; Bernardes M; Gonçalves MJ; Mouriño-Rodriguez C; Araújo F; Raposo A; Barcelos A; Couto M; Abreu P; Otón-Sanchez T; Macieira C; Ramos F; Branco JC; Silva JA; Canhão H; Calvo-Alén J; ;
Arthritis Care Res (Hoboken); 2015 Aug; 67(8):1180-5. PubMed ID: 25581417
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of complement activation products in Chinese patients with systemic lupus erythematosus.
Li J; An L; Zhang Z
Clin Exp Rheumatol; 2014; 32(1):48-53. PubMed ID: 23981509
[TBL] [Abstract][Full Text] [Related]
17. Performance of the 2012 Systemic Lupus International Collaborating Clinics and the 1997 American College of Rheumatology classification criteria for systemic lupus erythematosus in a real-life scenario.
Amezcua-Guerra LM; Higuera-Ortiz V; Arteaga-García U; Gallegos-Nava S; Hübbe-Tena C
Arthritis Care Res (Hoboken); 2015 Mar; 67(3):437-41. PubMed ID: 25073545
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the European League Against Rheumatism/American College of Rheumatology-2019 classification criteria in patients with childhood-onset systemic lupus erythematosus: a single-center retrospective study.
Ohara A; Iwata N; Sugiura S; Abe N; Nakaseko H; Kawabe S
Clin Rheumatol; 2022 Aug; 41(8):2483-2489. PubMed ID: 35377008
[TBL] [Abstract][Full Text] [Related]
19. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy.
Buyon JP; Tamerius J; Ordorica S; Young B; Abramson SB
Arthritis Rheum; 1992 Jan; 35(1):55-61. PubMed ID: 1731815
[TBL] [Abstract][Full Text] [Related]
20. What is the clinical significance of anti-Sm antibodies in systemic lupus erythematosus? A comparison with anti-dsDNA antibodies and C3.
Flechsig A; Rose T; Barkhudarova F; Strauss R; Klotsche J; Dähnrich C; Schlumberger W; Enghard P; Burmester GR; Hiepe F; Biesen R
Clin Exp Rheumatol; 2017; 35(4):598-606. PubMed ID: 28281463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
